Anvisa determined, on Wednesday (16), that the sale of weight loss pens need to have retention of revenue. The decision was made unanimously.
Currently, the consumer was already required to show the medical order to the pharmacist at the time of purchase. The discussion of retention had been started a month ago.
The directors of the organ discussed criteria for prescription, control, packaging and labeling of substances based on substances classified as antimicrobials of use under prescription, isolated or in association, as mentioned above.
With the proposal approved, pharmacies should have drug recipes as Ozepic, Monjaro and Wegovy .
Data from Anvisa herself point out that 32% of adverse cases notifications in Brazil involve the use of these drugs not indicated in a package insert. The index is more than triple from the global average, which is 10%.
*Update
This content was originally published in Anvisa now requires retention of revenue in the sale of weight loss pens on the CNN Brazil website.
Source: CNN Brasil
I’m James Harper, a highly experienced and accomplished news writer for World Stock Market. I have been writing in the Politics section of the website for over five years, providing readers with up-to-date and insightful information about current events in politics. My work is widely read and respected by many industry professionals as well as laymen.
